The roles of different actors in developing new treatments for drug-resistant infections
- Onyebuchi Chukwu, Former Minister of Health, Professor of Orthopaedic Surgery, Alex Ekwueme Federal University Ndufu Alike, (Nigeria)
- Prabhavathi Fernandes, Formerly at Abbott, Bristol Myers Squibb and Cempra (USA)
- Rohit Malpani, Independent Consultant and UNITAID Board Member (France)
Moderator: Peter Beyer, Senior Advisor, AMR Division, WHO (Switzerland)
Antibiotics are a vital component of modern medicine and are essential for ensuring we remain prepared for future pandemics. Through government funding via CARB-X and BARDA (push funding), as well as private sector-led investment via the AMR Action Fund, several new antibiotics are being helped to obtain regulatory approval. However, revenue generated by new antibiotics is still not considered sufficiently profitable by commercial developers to address the unmet need. The question remains to be answered: what role can different actors play to viably fund the development of new antibiotics and secure global equitable access to these life-saving drugs?
In this AMR Discussion webinar, the panelists discussed the roles industry, the public sector and not-for-profits can play in developing and ensuring access to new antibiotics and how the three alone and together can work to achieve this goal.